These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29945143)

  • 21. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
    Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
    Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
    Ou WC; Brown DM; Payne JF; Wykoff CC
    Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal.
    Vaz-Pereira S; Marques IP; Matias J; Mira F; Ribeiro L; Flores R
    Eur J Ophthalmol; 2017 Nov; 27(6):756-761. PubMed ID: 28315518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
    Li F; Sun M; Guo J; Ma A; Zhao B
    Curr Eye Res; 2017 Aug; 42(8):1174-1178. PubMed ID: 28441077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.
    Campochiaro PA; Sophie R; Pearlman J; Brown DM; Boyer DS; Heier JS; Marcus DM; Feiner L; Patel A;
    Ophthalmology; 2014 Jan; 121(1):209-219. PubMed ID: 24112944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion in a Chinese Population.
    Gu X; Yu X; Song S; Dai H
    Ophthalmic Res; 2017; 58(1):8-14. PubMed ID: 28334720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Serum Inflammation-Based Factors in Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion and Its Subtypes.
    Rao J; Wu N; Qu X; Hu Y; Wu Y; Cheng Y; Yan L; Huang H; Li S; Shi L; Wu X
    Ophthalmic Res; 2021; 64(2):237-245. PubMed ID: 32506058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study.
    Feltgen N; Hattenbach LO; Bertelmann T; Callizo J; Rehak M; Wolf A; Berk H; Eter N; Lang GE; Pielen A; Schmitz-Valckenberg S; Quiering C; Rose U; Hoerauf H;
    Acta Ophthalmol; 2018 Dec; 96(8):e933-e941. PubMed ID: 29855153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab.
    Narayanan R; Kelkar A; Abbas Z; Goel N; Soman M; Naik N; Sudhalkar A; Walinjkar J; Shah U; Maksane N
    BMC Ophthalmol; 2021 Jan; 21(1):33. PubMed ID: 33435908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluctuations in Macular Thickness in Patients with Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Chen AX; Greenlee TE; Conti TF; Briskin IN; Singh RP
    Ophthalmol Retina; 2020 Dec; 4(12):1158-1169. PubMed ID: 32480014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion.
    Lloyd Clark W; Liu M; Kitchens J; Wang PW; Haskova Z
    BMC Ophthalmol; 2019 Jan; 19(1):11. PubMed ID: 30621653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
    Song S; Yu X; Zhang P; Gu X; Dai H
    BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
    Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Boscia F; Gerding H; Monés J; Tadayoni R; Priglinger S; Wenzel A; Barnes E; Pilz S; Stubbings W; Pearce I;
    Ophthalmology; 2016 May; 123(5):1101-11. PubMed ID: 26896124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
    Thach AB; Yau L; Hoang C; Tuomi L
    Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visual and Anatomic Outcomes following Cataract Surgery in Patients with Pre-operative Macular Edema Due to Retinal Vein Occlusions Managed with Intravitreal anti-VEGF.
    Starr MR; Mahr MA; Iezzi R; Barkmeier AJ; Bakri SJ
    Semin Ophthalmol; 2020 May; 35(4):205-209. PubMed ID: 32721186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes in Retinal Vein Occlusions Presenting with Poor Visual Acuity Treated with Anti-Vascular Endothelial Growth Factor Therapy: Prognosis and Predictive Factors.
    Light JG; Tian J; Wenick AS
    Ophthalmol Retina; 2021 Sep; 5(9):888-900. PubMed ID: 33227561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
    Pichi F; Elbarky AM; Elhamaky TR
    Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
    Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
    Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion.
    Liu W; Li Y; Cao R; Bai Z; Liu W
    Medicine (Baltimore); 2020 May; 99(21):e20222. PubMed ID: 32481293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.